Novo Nordisk A/S Stock News

Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is see

Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss trea

Novo Nordisk (NYSE: NVO ) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial. The big news here is the company's oral weight

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming blockbuster drug Wegovy. An early-s

Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company's plans to cement its prime position in

Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.

Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Investors are excited about the opportunity for Viking's experimental weight-loss drug VK2735. Viking doesn't compare favorably against Lilly and Novo Nordisk in most categories.

A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.

Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish d

Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.

The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish d